Innate Pharma specializes in immuno oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body s own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first in class antibodies in clinical development in immuno oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had employees as at March , . The company is listed on Euronext Paris.
Quote | Innate Pharma (OTCMKTS:IPHYF)
Last: | $1.9301 |
---|---|
Change Percent: | 0.0% |
Open: | $1.9301 |
Close: | $1.9301 |
High: | $1.9301 |
Low: | $1.9301 |
Volume: | 500 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Innate Pharma (OTCMKTS:IPHYF)
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Message Board Posts | Innate Pharma (OTCMKTS:IPHYF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest Innate Pharma (IPHYF) Headlines INNATE PHARMA : raises 20.3 million in a | Stock_Tracker | investorshangout | 03/10/2014 10:53:12 AM |
chartguy89: IPHYF 15.058 Stock Charts $IPHYF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 4:38:31 AM |
chartguy89: IPHYF Stock Charts Last: -0.78 Thursday, February 27, 2014 at 3:45:56 AM $IPHYF | chartguy89 | investorshangout | 02/27/2014 8:46:08 AM |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...